Allogene Therapeutics
Maxwell Louie is an accomplished professional in the field of quality control and equipment qualification with extensive experience in the biotechnology industry. Currently serving as Associate Director of QC Instrument Qualification and Validation at Allogene Therapeutics since February 2019, Maxwell previously held the role of Manager of Commercial QC Instrument Qualification and Software Validation at Intarcia Therapeutics, Inc. from August 2017 to February 2019. Prior to that, Maxwell dedicated a decade at Genentech, progressing from Laboratory Operations Senior Analyst to Senior QC Equipment Lead, overseeing equipment qualification and validation processes, facilitating computer system validations, and managing stability studies in compliance with ICH guidelines. Maxwell holds a Bachelor's degree in Forensic Chemistry from California State University-Sacramento.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.